BioStem Technologies to Present at the Centri Capital Conference
BioStem Technologies (OTC: BSEM), a MedTech company specializing in placental-derived products for advanced wound care, has announced its participation in the upcoming Centri Capital Conference at Nasdaq headquarters in New York City.
CEO Jason Matuszewski will deliver a presentation on April 22, 2025, at 10:30 AM ET and conduct one-on-one meetings with interested parties. The company's core technology, BioREtain®, is their proprietary processing method focused on maintaining growth factors and preserving tissue structure.
BioStem's portfolio includes AmnioWrap2™, VENDAJE®, VENDAJE AC®, and VENDAJE OPTIC® products, all processed at their FDA registered and AATB accredited facility in Pompano Beach, Florida. The company maintains quality management systems and standard operating procedures accredited by the American Association of Tissue Banks, following current Good Tissue Practices and Good Manufacturing Processes.
BioStem Technologies (OTC: BSEM), un'azienda MedTech specializzata in prodotti derivati dalla placenta per la cura avanzata delle ferite, ha annunciato la sua partecipazione alla prossima Centri Capital Conference presso la sede del Nasdaq a New York City.
Il CEO Jason Matuszewski terrà una presentazione il 22 aprile 2025 alle 10:30 ET e incontrerà personalmente le parti interessate. La tecnologia principale dell'azienda, BioREtain®, è un metodo proprietario di lavorazione focalizzato sul mantenimento dei fattori di crescita e sulla conservazione della struttura tissutale.
Il portafoglio prodotti di BioStem comprende AmnioWrap2™, VENDAJE®, VENDAJE AC® e VENDAJE OPTIC®, tutti processati nel loro stabilimento registrato FDA e accreditato AATB a Pompano Beach, Florida. L'azienda applica sistemi di gestione della qualità e procedure operative standard accreditate dall'American Association of Tissue Banks, seguendo le attuali Buone Pratiche Tissutali e di Produzione.
BioStem Technologies (OTC: BSEM), una empresa MedTech especializada en productos derivados de la placenta para el cuidado avanzado de heridas, ha anunciado su participación en la próxima Centri Capital Conference en la sede de Nasdaq en Nueva York.
El CEO Jason Matuszewski realizará una presentación el 22 de abril de 2025 a las 10:30 AM ET y mantendrá reuniones individuales con las partes interesadas. La tecnología principal de la compañía, BioREtain®, es su método propio de procesamiento enfocado en mantener los factores de crecimiento y preservar la estructura del tejido.
El portafolio de BioStem incluye los productos AmnioWrap2™, VENDAJE®, VENDAJE AC® y VENDAJE OPTIC®, todos procesados en su instalación registrada por la FDA y acreditada por AATB en Pompano Beach, Florida. La empresa mantiene sistemas de gestión de calidad y procedimientos operativos estándar acreditados por la American Association of Tissue Banks, siguiendo las actuales Buenas Prácticas de Tejidos y de Manufactura.
BioStem Technologies (OTC: BSEM)는 고급 상처 치료를 위한 태반 유래 제품을 전문으로 하는 메드테크 회사로, 뉴욕시 나스닥 본사에서 열리는 Centri Capital Conference에 참여한다고 발표했습니다.
CEO 제이슨 마투제프스키는 2025년 4월 22일 오전 10시 30분(동부시간)에 발표를 진행하며, 관심 있는 관계자들과 일대일 미팅을 가질 예정입니다. 회사의 핵심 기술인 BioREtain®은 성장 인자를 유지하고 조직 구조를 보존하는 독자적인 처리 방법입니다.
BioStem의 제품군에는 AmnioWrap2™, VENDAJE®, VENDAJE AC®, VENDAJE OPTIC®가 포함되어 있으며, 모두 플로리다 팜파노 비치에 위치한 FDA 등록 및 AATB 인증 시설에서 처리됩니다. 회사는 미국 조직은행 협회(AATB) 인증을 받은 품질 관리 시스템과 표준 운영 절차를 유지하며, 현재의 우수 조직 관리 및 제조 공정을 준수합니다.
BioStem Technologies (OTC : BSEM), une entreprise MedTech spécialisée dans les produits dérivés du placenta pour les soins avancés des plaies, a annoncé sa participation à la prochaine Centri Capital Conference au siège du Nasdaq à New York.
Le PDG Jason Matuszewski présentera le 22 avril 2025 à 10h30 ET et tiendra des réunions individuelles avec les parties intéressées. La technologie principale de l’entreprise, BioREtain®, est une méthode propriétaire de traitement visant à maintenir les facteurs de croissance et à préserver la structure des tissus.
Le portefeuille de BioStem comprend les produits AmnioWrap2™, VENDAJE®, VENDAJE AC® et VENDAJE OPTIC®, tous traités dans leur installation enregistrée auprès de la FDA et accréditée AATB à Pompano Beach, en Floride. L’entreprise dispose de systèmes de gestion de la qualité et de procédures opérationnelles standard accrédités par l’American Association of Tissue Banks, suivant les Bonnes Pratiques Tissulaires et les Bonnes Pratiques de Fabrication en vigueur.
BioStem Technologies (OTC: BSEM), ein MedTech-Unternehmen, das sich auf plazentabasierten Produkte für die fortschrittliche Wundversorgung spezialisiert hat, hat seine Teilnahme an der kommenden Centri Capital Conference im Nasdaq-Hauptquartier in New York City angekündigt.
CEO Jason Matuszewski wird am 22. April 2025 um 10:30 Uhr ET eine Präsentation halten und Einzelgespräche mit Interessenten führen. Die Kerntechnologie des Unternehmens, BioREtain®, ist ein proprietäres Verarbeitungsverfahren, das darauf abzielt, Wachstumsfaktoren zu erhalten und die Gewebestruktur zu bewahren.
Das Portfolio von BioStem umfasst die Produkte AmnioWrap2™, VENDAJE®, VENDAJE AC® und VENDAJE OPTIC®, die alle in ihrer FDA-registrierten und AATB-akkreditierten Einrichtung in Pompano Beach, Florida, verarbeitet werden. Das Unternehmen unterhält Qualitätsmanagementsysteme und standardisierte Betriebsverfahren, die von der American Association of Tissue Banks akkreditiert sind und den aktuellen Good Tissue Practices sowie Good Manufacturing Practices entsprechen.
- None.
- None.
The presentation will be webcast at 10:30 AM ET on April 22, 2025
POMPANO BEACH, Fla., April 21, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care, is pleased to announce that its Chief Executive Officer, Jason Matuszewski, will be presenting and holding one-on-one meetings at the upcoming Centri Capital Conference on April 22, 2025, taking place at the Nasdaq headquarters in New York City.
BioStem Technologies Presentation Access:
- Presenter: Jason Matuszewski, Chief Executive Officer
- Date: Tuesday, April 22, 2025
- Time: 10:30 AM ET
- Webcast Link & Archive: HERE
- 1-on-1 Meeting Request: adam@holdsworthco.com
Join BioStem’s Distribution List & Social Media:
To follow the latest developments at BioStem, sign-up to the Company’s email distribution list HERE, and follow us on Twitter and LinkedIn.
About BioStem Technologies, Inc. (OTC: BSEM):
BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts. The Company is focused on manufacturing products that change lives, leveraging its proprietary BioREtain® processing method. BioREtain® has been developed by applying the latest research in advanced wound care, focused on maintaining growth factors and preserving tissue structure. BioStem Technologies’ quality management system and standard operating procedures have been reviewed and accredited by the American Association of Tissue Banks (“AATB”). These systems and procedures are established per current Good Tissue Practices (“cGTP”) and current Good Manufacturing Processes (“cGMP”). Our portfolio of quality brands includes AmnioWrap2™, VENDAJE®, VENDAJE AC®, and VENDAJE OPTIC®. Each BioStem Technologies placental allograft is processed at the Company’s FDA registered and AATB accredited site in Pompano Beach, Florida.
For more information visit biostemtechnologies.com and follow us on Twitter and LinkedIn.
BioStem Technologies, Inc.
Phone: 954-380-8342
Website: http://www.biostemtechnologies.com
E-Mail: info@biostemtech.com
Twitter: @BSEM_Tech
Facebook: BioStem Technologies
Investor Relations
Adam Holdsworth
Adam@holdsworthco.com
917-497-9287
FAQ
When and where is BioStem Technologies (BSEM) presenting at the Centri Capital Conference?
What products are in BioStem Technologies' (BSEM) current portfolio?
What is BioStem Technologies' (BSEM) BioREtain® processing method?
What certifications does BioStem Technologies' (BSEM) manufacturing facility have?
How can investors follow BioStem Technologies' (BSEM) latest developments?
